Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates

On May 7, Stoke Therapeutics, Inc. (NASDAQ:STOK) reported Q1 results and concern updates. The institution stated that 4 years of information from “Phase 1/2a open-label extension” studies revealed statistically meaningful gains successful cognition and behavior, on with recurrent seizure drops from baseline. “Zorevunersen” remained mostly good tolerated, with immoderate patients treated for much than 5 years.

Chief Executive Officer and Director Ian F. Smith said the information “suggest that zorevunersen whitethorn alteration the people of Dravet syndrome,” noting seizure reductions and imaginable developmental benefits.

The institution besides said “Phase 3 EMPEROR” enrollment of astir 150 patients is expected to beryllium completed successful June 2026. It supports mid-2027 information and a planned rolling US NDA submission successful Q1 of 2027.

As of March 31, 2026, Stoke Therapeutics, Inc. (NASDAQ:STOK) had $411 cardinal successful currency and investments, including $80.7 cardinal raised by ATM sales. It is backing operations into 2028.

Stoke Therapeutics, Inc. (NASDAQ:STOK) is simply a biotechnology institution that conducts probe and develops treatments for familial diseases.

While we admit the imaginable of STOK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.